TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27184343

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus biomarker feedback (SHSe feedback)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Enhanced-PAM (six asthma education/smoking cessation calls + repeat SHSe feedback)
Number of subjects: 341

Group type: COMPARATOR
Intervention: PAM (six asthma education calls)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Teachable Moment (TM) effect
Number of subjects: 341
Study: 25306220

Group type: EXPERIMENTAL
Intervention: Individualised best practice ergonomic intervention plus 3×20 minute weekly, progressive neck/shoulder girdle exercise group sessions for 12 weeks.
Number of subjects: 640

Group type: COMPARATOR
Intervention: Individualised best practice ergonomic intervention plus 1‐hour weekly health information sessions for 12 weeks.
Number of subjects: 640
Study: 22430687

Group type: EXPERIMENTAL
Intervention: Freeze-dried dura mater allograft (experimental group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Open debridement (control group)
Number of subjects: 12
Study: 20547399

Group type: EXPERIMENTAL
Intervention: PCV‐11
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 1111
Study: 18938214

Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 15968010

Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 168
Study: 12187458

Group type: EXPERIMENTAL
Intervention: Diagnosis threat group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Neutral test directions group
Number of subjects: 36
Study: 9735969

Group type: EXPERIMENTAL
Intervention: Self-report version of the BASIS-32
Number of subjects: 120

Group type: COMPARATOR
Intervention: Interview version of the BASIS-32
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both self-report and interview versions of the BASIS-32
Number of subjects: 120
Study: 7713242

Group type: EXPERIMENTAL
Intervention: Methazolamide 50 mg q.i.d. for 2 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2655521

Group type: EXPERIMENTAL
Intervention: Intestinal decontamination (group 3) with neomycin, polymyxin E, and nalidixic acid
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: No intervention (group 1)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Intestinal decontamination (group 3)
Number of subjects: 124
Study: 591936

Group type: EXPERIMENTAL
Intervention: Marijuana extract calibrated to 0.3 mg/kg delta‐9‐tetrahydrocannabinol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Association‐overt rehearsal procedure
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo conditions
Number of subjects: 16
Study: 30658669

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 280

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 280
Study: 28662531

Group type: EXPERIMENTAL
Intervention: Maximal leg strength program (80-95% of 1-RM, 1-3 repetitions, 3-6 sets, 3-4 min rest between sets) performed twice a week for 10 weeks.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no additional strength training).
Number of subjects: 22
Study: 25366615

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/day with enteral nutrition (EN) and parenteral nutrition (PN)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 130
Study: 22837543

Group type: EXPERIMENTAL
Intervention: Buteyko breathing technique
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pranayama breathing technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (routine pharmacological management)
Number of subjects: 120
Study: 21431373

Group type: EXPERIMENTAL
Intervention: Single high‐dosage extracorporeal shockwave therapy (0.3 mJ/mm(2))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Two sessions of low‐dosage extracorporeal shockwave therapy (0.2 mJ/mm(2))
Number of subjects: 30
Study: 19398066

Group type: EXPERIMENTAL
Intervention: Low Frequency Group (2 times/week for 5 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: High Frequency Group (5 times/week for 2 weeks)
Number of subjects: 30
Study: 16691091

Group type: EXPERIMENTAL
Intervention: Manual therapy (MT; mainly spinal mobilization)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT; mainly exercise therapy)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Continued care by the general practitioner (GP; analgesics, counseling and education)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Continued care by the general practitioner (GP)
Number of subjects: 183
Study: 14586663

Group type: EXPERIMENTAL
Intervention: 60-minute stationary cycle ergometry session at 65% of Vdot;O(2max)
Number of subjects: 0
Study: 10670390

Group type: EXPERIMENTAL
Intervention: Care Planning Simulation System (CPSS)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Nutrition Care Planning Tutorial (NCPT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: CPSS-I and NCPT-I groups (interns who started clinical rotations immediately after orientation)
Number of subjects: 108

Group type: COMPARATOR
Intervention: CPSS-D and NCPT-D groups (interns who began their clinical rotations later)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: CPSS
Number of subjects: 108
Study: 8974552

Group type: EXPERIMENTAL
Intervention: Individual consultations with a family physician in his office (Group I)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Group sessions with a physician and a dietician (Group II)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Individual consultations with a dietician (Group III)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Counseling (general outcome across all groups)
Number of subjects: 135
Study: 1405268

Group type: EXPERIMENTAL
Intervention: Intravenous large dose streptokinase
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: QRS score system
Number of subjects: 57
Study: 3894494

Group type: EXPERIMENTAL
Intervention: Cimetidine (Tagamet) 300 mg q.i.d.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Mylanta II 10 ml q.i.d.
Number of subjects: 38
Study: 29017067

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 28165762

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 1-6 mg daily
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR)
Number of subjects: 83
Study: 26607762

Group type: EXPERIMENTAL
Intervention: Active recruitment (contacting eligible families directly)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Passive recruitment (informing the community through flyers, public events, media)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Media-led enquiries
Number of subjects: 194

Group type: COMPARATOR
Intervention: Information seen at schools or GP surgeries
Number of subjects: 194
Study: 23182965

Group type: EXPERIMENTAL
Intervention: Hospital-based intervention (HB)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Community-based intervention (CB)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 99
Study: 21989306

Group type: EXPERIMENTAL
Intervention: Electronic version of the Faces Pain Scale-Revised (FPS-R)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Paper version of the Faces Pain Scale-Revised (FPS-R)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Preference for the version of FPS-R
Number of subjects: 202
Study: 18419443

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B inhalation (twice a week until neutrophil counts >300 cells/mm3)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B inhalation (on-treatment analysis)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo inhalation (on-treatment analysis)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 271
Study: 16850791

Group type: EXPERIMENTAL
Intervention: Computer anthropometry monitoring
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Restoration treatment
Number of subjects: 44
Study: 12949595

Group type: EXPERIMENTAL
Intervention: Psychosocial group intervention (6-week duration including health education, coping skills training, stress management, and psychological support)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 50
Study: 10699133

Group type: EXPERIMENTAL
Intervention: PCR assay for Bordetella pertussis
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: 3+ positive PCR results
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: 2+ positive PCR results
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: 1+ positive PCR results
Number of subjects: 392

Group type: COMPARATOR
Intervention: Conventional culture
Number of subjects: 392
Study: 8792943

Group type: EXPERIMENTAL
Intervention: Prescription medications (self-reported use)
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Gender comparison in medication use
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Factors associated with greater medication use
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Age-related medication use
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Gender-related medication use
Number of subjects: 1360
Study: 1634705

Group type: EXPERIMENTAL
Intervention: Milacemide 1200 mg/day for 1 month
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 6378805

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1-selective blocker)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 585
Study: 3949566

Group type: EXPERIMENTAL
Intervention: Chemotherapy only
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Radiotherapy only
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Combined radiotherapy and chemotherapy
Number of subjects: 202

Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Perineal irradiation
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Patients with tumors within 2 cm of the anorectal junction
Number of subjects: 202

Group type: COMPARATOR
Intervention: Patients with tumors more than 2 cm from the anus
Number of subjects: 202
Study: 31953532

Group type: EXPERIMENTAL
Intervention: BeEAM regimen
Number of subjects: 168

Group type: COMPARATOR
Intervention: BEAM regimen
Number of subjects: 168
Study: 29441742

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) combined with low-dose corticosteroids
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cyclosporine (CsA) combined with low-dose corticosteroids
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 27039125

Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 25765590

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg (maximum 100 mg) subcutaneously every 12 hours for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional anticoagulation (intravenous heparin followed by oral warfarin for 3 months)
Number of subjects: 60
Study: 23534831

Group type: EXPERIMENTAL
Intervention: Video feedback intervention during the Family Check-Up (FCU) protocol
Number of subjects: 79

Group type: COMPARATOR
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 79
Study: 21183917

Group type: EXPERIMENTAL
Intervention: Omaron (25 mg of cinnarizine and 400 mg of piracetam), 1 tablet 3 times a day for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no nootropics)
Number of subjects: 33
Study: 18849119

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid PET/CT
Number of subjects: 0
Study: 16688202

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) at 3, 4, and 5 l/min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP) at 6 cm H2O
Number of subjects: 18
Study: 12568837

Group type: EXPERIMENTAL
Intervention: L‐carnitine therapy 2 g/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10982201

Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 62
Study: 9816321

Group type: EXPERIMENTAL
Intervention: UFT at a dose of 400 mg/m2/day administered as three divided doses (every 8 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single daily dosing of UFT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UFT at a dose of 300 mg/m2/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UFT at a dose of 400 mg/m2/day
Number of subjects: 0
Study: 1466210

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25-0.50 mg sublingually
Number of subjects: 62

Group type: COMPARATOR
Intervention: Diazepam 5-10 mg orally
Number of subjects: 62
Study: 6717216

Group type: EXPERIMENTAL
Intervention: Moxalactam (30 mg/kg) for 3 doses postoperatively
Number of subjects: 30

Group type: COMPARATOR
Intervention: Moxalactam (30 mg/kg) for 6 doses postoperatively
Number of subjects: 30
Study: 30341029

Group type: EXPERIMENTAL
Intervention: Diabetic patients receiving metformin
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Diabetic patients not receiving metformin
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Nondiabetic patients
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Overall survival factors
Number of subjects: 1600
Study: 28667826

Group type: EXPERIMENTAL
Intervention: Intensive counselling by a practice nurse (PN)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Brief advice by a general practitioner (GP)
Number of subjects: 295
Study: 25825138

Group type: EXPERIMENTAL
Intervention: Compressive cryotherapy (CC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard ice wrap (IW)
Number of subjects: 46
Study: 23370528

Group type: EXPERIMENTAL
Intervention: L-Name (20 μg min⁻¹ kg⁻¹) during OGTT
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: L-Name (at rates of 2.5, 5, 10 and 20 μg min⁻¹ kg⁻¹) during hyperglycaemic clamps
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline during OGTT
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline during hyperglycaemic clamps
Number of subjects: 29
Study: 22214253

Group type: EXPERIMENTAL
Intervention: Eucommia extract 500 mg three times daily for eight weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Eucommia extract 0.5% w/v
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Eucommia extract 1 g three times daily for two weeks
Number of subjects: 54
Study: 19597364

Group type: EXPERIMENTAL
Intervention: Psychodynamic Group Therapy (PGT) plus clonazepam
Number of subjects: 57

Group type: COMPARATOR
Intervention: Clonazepam
Number of subjects: 57
Study: 16899833

Group type: EXPERIMENTAL
Intervention: Chronic cough patients (all groups)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chronic cough patients (group 1: intrapulmonary diseases)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chronic cough patients (group 2: extrapulmonary diseases)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chronic cough patients (group 3: unexplained cough)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subjects (nonsmoking, asymptomatic)
Number of subjects: 24
Study: 14746420

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 94

Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 94
Study: 11669470

Group type: EXPERIMENTAL
Intervention: Remifentanil (target plasma concentrations: 0, 1.2, 1.8, 2.4, 3, 3.6, 4.8, and 6 ng/ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Remifentanil (target plasma concentrations)
Number of subjects: 16
Study: 9721772

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogen (n = 20)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 5 mg of simvastatin (n = 18)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combination therapy (n = 17)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Estrogen treatment
Number of subjects: 55
Study: 8032829

Group type: EXPERIMENTAL
Intervention: One instillation of thiotepa at the time of resection
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Five instillations of thiotepa (one at time of resection and then at 3-month intervals for one year)
Number of subjects: 417

Group type: COMPARATOR
Intervention: No thiotepa (control group)
Number of subjects: 417
Study: 2512938

Group type: EXPERIMENTAL
Intervention: enprostil (35 micrograms)
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 958162

Group type: EXPERIMENTAL
Intervention: Porfiromycin (75 mg/M2 every 6-8 weeks as a single bolus i.v. injection)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Mitomycin-C (22.5 mg/M2 every 6-8 weeks as a single bolus i.v. injection)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Mitomycin-C
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Porfiromycin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 63
Study: 31008902

Group type: EXPERIMENTAL
Intervention: High-quality foster care
Number of subjects: 127

Group type: COMPARATOR
Intervention: Care as usual (institutional care)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Age of placement into foster care
Number of subjects: 127
Study: 28928303

Group type: EXPERIMENTAL
Intervention: Vitamin D status measurement (25‐hydroxyvitamin D)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Sociobehavioral risk factors analysis
Number of subjects: 400
Study: 26185429

Group type: EXPERIMENTAL
Intervention: teriparatide 20 μg/day
Number of subjects: 207

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 207
Study: 23647283

Group type: COMPARATOR
Intervention: Self-help treatment administered in a group
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: Longer treatment duration
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: African American participants
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: Lower level of education
Number of subjects: 1073
Study: 21722033

Group type: EXPERIMENTAL
Intervention: Culturally enriched FRIENDS for Life program
Number of subjects: 533

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 533
Study: 19644647

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine pre‐peritoneally after placing mesh
Number of subjects: 53

Group type: COMPARATOR
Intervention: Saline pre‐peritoneally after placing mesh
Number of subjects: 53
Study: 17127811

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0
Study: 15383190

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF)
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Sustained-release oral morphine (SRM)
Number of subjects: 1220
Study: 11744907

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 117

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 117
Study: 9247842

Group type: EXPERIMENTAL
Intervention: Oral tolterodine 3.2 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral tolterodine 6.4 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral tolterodine 12.8 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral tolterodine (14C) 5 mg
Number of subjects: 17
Study: 7682488

Group type: EXPERIMENTAL
Intervention: L-carnitine (6 g daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propafenone (900 mg daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propafenone (900 mg daily) plus L-carnitine (6 g daily)
Number of subjects: 30
Study: 3117401

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 20‐30 mg adriamycin for 4 weeks or 2 years
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 20 mg mitomycin C for 4 weeks or 2 years
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (no instillation)
Number of subjects: 259
Study: 31870492

Group type: EXPERIMENTAL
Intervention: Intracoronary tenecteplase (TNK) 4 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intracoronary saline placebo
Number of subjects: 40
Study: 29480503

Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills (CLAS) program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent-focused treatment (PFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community-based treatment as usual (TAU)
Number of subjects: 0
Study: 26086285

Group type: EXPERIMENTAL
Intervention: Alizapride 100 mg
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study: 25330088

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23556437

Group type: EXPERIMENTAL
Intervention: Vitamin D₃ (400 IU/d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vitamin D₂ (400 IU/d)
Number of subjects: 39
Study: 19787711

Group type: EXPERIMENTAL
Intervention: Non-surgical therapy (continence pessary, pelvic floor muscle training or combined)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: QUID Stress scores
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: QUID Urge scores
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: QUID Total, Stress, and Urge scores
Number of subjects: 444
Study: 18382004

Group type: EXPERIMENTAL
Intervention: Comprehensive psychosocial services
Number of subjects: 541

Group type: COMPARATOR
Intervention: Usual community care
Number of subjects: 541
Study: 16735085

Group type: EXPERIMENTAL
Intervention: 116E (10^5 FFu)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: I321 (10^5 FFu)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90